Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis

[1]  Thomas M. Ludden,et al.  Pharmacokinetics of Quinidine in Male Patients , 1992, Clinical pharmacokinetics.

[2]  M L Crismon,et al.  Postinduction Carbamazepine Clearance in an Adult Psychiatric Population , 1991, Pharmacotherapy.

[3]  I E Leppik,et al.  Pharmacokinetics of Felbamate, a Novel Antiepileptic Drug: Application of Mixed‐Effect Modeling to Clinical Trials , 1989, Pharmacotherapy.

[4]  R B Smith,et al.  An evaluation of population pharmacokinetics in therapeutic trials. Part III. Prospective data collection versus retrospective data assembly , 1989, Clinical pharmacology and therapeutics.

[5]  R. Banagale,et al.  The population pharmacokinetics of theophylline in neonates and young infants , 1989, Journal of Pharmacokinetics and Biopharmaceutics.

[6]  T. Grasela,et al.  An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies , 1986, Clinical pharmacology and therapeutics.

[7]  Lewis B. Sheiner,et al.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[8]  T F Blaschke,et al.  Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates. , 1992, Developmental pharmacology and therapeutics.

[9]  M. A. Mergener,et al.  Pharmacokinetics of the Digoxin-Quinidine Interaction via Mixed-Effect Modelling , 1992, Clinical pharmacokinetics.

[10]  M. Crismon,et al.  Population pharmacokinetics of lithium. , 1991, Clinical pharmacy.